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Fungal septicaemia is a serious and potentially fatal condition. We report 4 cases in patients with Cystic Fibrosis (CF) associated with
totally implantable venous access device system (TIVADS).
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1.1. Case 1
Twenty four year old male presented with increasing
cough, green sputum, tiredness and reduced appetite for
10 days. He had a past medical history of CF-related diabetes
mellitus and liver disease with portal hypertension. He was a
former intravenous illicit drug user on methadone. Clinically
he had a normal temperature, blood pressure, and pulse with
an oxygen saturation of 94% on air. The TIVADS entry port
was noted to be erythematous with no clear signs of
infection. Intravenous antibiotics were started based on the last
sputum culture sensitivities. He failed to improve despite
2 weeks of treatment and developed a low-grade fever. Blood
cultures from TIVADS and peripheral veins grew candida
species later identified as Candida glabrata. The TIVADS
was removed and antifungals started (amphotericin B was
changed to voriconazole due to renal impairment). Methicillin
resistant staphylococcus aureus was isolated from sputum and
linezolid commenced. He made an eventual recovery.⁎ Corresponding author. Tel.: +44 1179595284; fax: +44 1179595873.
E-mail address: khalidgbr@doctors.org.uk (K.A. Gaber).
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Twenty three year old female was admitted with increasing
shortness of breath despite 2weeks of intravenous antibiotics at
home. She reported that her TIVADS had been red and painful
and had a rigor on accessing the port. The port entry site was
noted to be red, tender and warm. She was apyrexial with a
mildly elevated C-reactive protein of 27 mg/l (n=0–12). After
a normal linogram, antibiotics were changed in accordance
with microbiology advice. Line and peripheral blood cultures
revealedCandida glabrata. As this was her fourth TIVADS, it
was hoped to conserve the line and treat with anti-fungal drugs
alone. This proved unsuccessful and the TIVADS was re-
moved. She developed a skin rash secondary to fluconazole. A
total of six weeks amphotericin B was given with good
response.
1.3. Case 3
Twenty-year-old female, whose disease course was com-
plicated by a resistant Pseudomonas aeruginosa and multiple
drug allergies, was admitted with left sided chest pain and
increasing sputum production. She was apyrexial with clinical
and radiological features of left lower lobe pneumonia. Theed by Elsevier B.V. All rights reserved.
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reactive protein was 20 mg/l. Appropriate antibiotics were
started. She failed to improve despite modifying antibiotic
regimen developing pyrexia, and feeling more unwell.
Multiple blood cultures grew two species ofCandida (albicans
and parapsillosis) The TIVADSwas removed and she received
Amphotericin B for 6 weeks with good improvement.
1.4. Case 4
Five-year-old child with 6-day history of nausea, vomit-
ing, and significant weight loss. On examination he was
apyrexial and mildly dehydrated with no signs of distress. He
was noted to have green nasal secretions, injected conjunc-
tivae, loose abdominal skin and to have lost 6 kg of weight in
2 months. No skin rashes or signs of meningism. Oxygen
saturations were 98% on air, respiratory rate 20/min, heart rate
110 beats per minute C-reactive protein b3 mg/l, white blood
cells 6.6×109/l (n=5–15), urea 6.6 mmol/l (2.5–6), creati-
nine 43 μmol/l (25–125) He was started with intravenous
fluids and antibiotics for a possible septicaemia. Repeated
blood cultures from TIVADS and peripheral veins were po-
sitive for Candida parapsillosis. The line was removed and
3 weeks of fluconazole given with rapid improvement.
2. Discussion
TIVADs are widely used in patients with CF to provide
intermittent venous access [1]. They are safe, effective and
well tolerated by CF patients [1,2] who regard them as goodTable 1
Cases summary
Case 1 Case 2
Age (years) 24 23
Sex M F
Gene d.508 d.508
Duration of CF disease (years) 18 23
Diabetes mellitus Y Y
HbA1c (%) 5.5 16.1
ABPA N N
BMI 19.4 23
Courses of intravenous antibiotics
in last 12 months
4 5
On long term azithromycin Y N
TIVAD
number 2 4
Duration 14 months 9 months
Bacterial colonisation
a) Pseudomonas Y Y
b) Staphylococcus N Y
Candida species Glabrata Glabrata
Isolated from
Peripheral blood culture Y Y
TIVAD blood culture Y Y
Treatment received Abizome (8 days)
Voriconazole (5 weeks)
Flucytosine (2
Amphtericin B
Treatment complication Renal toxicity Allergic reacti
ABPA (alleagic broncho pulmonary aspergillosis), BMI (body mass index), HBAalternatives to cannulae and long lines [3]. Local infection of
TIVADS is not uncommon but septicaemia is rare [4]. A
retrospective analysis of about 10 years experience involving
57 TIVADS implanted in 44 patients with CF showed a rate
of infection of one per 2984 catheter days with septicaemia
occurring in 5 devices (9%), one of which was fungal [4].
Another review of 87 catheters inserted over a 10 year period
reported 9 catheter-related infections and 2 cases of fungal
septicaemia requiring catheter removal [5].
A more recent multi-centre retrospective study involving
453 TIVADs inserted in 315 CF patients (1205 catheter
years) in 36 centres showed that fungal (candida) septicae-
mia was responsible for 66% of the 7.3% septicaemia cases
reported [6]. This study was unable to identify risk factors for
septicaemia. However, a smaller study showed that factors
such as disease severity, frequent antibiotic usage, malnutri-
tion, corticosteroid therapy, and diabetes mellitus were
associated with increased risk [4].
The clinical presentation of fungal septicaemia in our
patients was variable. In the three adult cases reported it was
similar to bacterial exacerbations but without response to
intravenous antibiotics. All were afebrile at presentation and
later developed a low-grade fever. The inflammatory
markers were not grossly abnormal. The highest levels of
C-reactive protein measured were 42, 69 and 44 mg/l, with
white cell counts of 5.4, 10 and 12.4 cells×109/l respectively.
No one was clinically severely unwell at any time during his
or her admission. The clinical presentation in the child (case
4) was different. It was of a systemic illness with nausea,
vomiting, dehydration and weight loss in the presence ofCase 3 Case 4
20 5
F M
d.508 d.508
17 5
Y N
5.3 NA
N N
16 16.8 (75th centile)
1 1
Y N
2 3
9 months 8 weeks
Y Y
Y Y
Parapsillosisand albicans Parapsillosis
Y Y
Y Y
0 days)
(6 weeks)
Amphotericin (6 weeks) Fluconazole (3 weeks)
on to flucytosine Hepatitis Nil
1C (glycocylated haemoglobin), Y (yes), N (no), NA (non applicable).
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diabetics on insulin (one badly controlled with HbA1c of
16.1 (normal range 3.8–6.4%)) and one (case 3) was on
long-term oral prednisolone (10 mg alternate days) (Table 1).
Candida species have the capacity to colonise the lumen
of tubular structures inserted in blood vessels such as
TIVADS. They attach to them and resist the immune system
by forming biofilms, which are three dimensional structures
containing cells impeded in a matrix of extra-cellular poly-
meric substances they have produced [7]. Biofilms resist the
antimicrobial agents by delaying their penetration through
the biofilm matrix and altering the growth rate of biofilm
organisms hence reducing the uptake of antimicrobial agents
[7]. Part of biofilms, containing embedded organisms, may
detach from the colonised medical device and circulate
causing septicaemia. Therefore when vascular devices are
infected, antimicrobial therapy is not sufficient, they have to
be removed.
Fungal septicaemia in patients with TIVADs is serious and
requires aggressive treatment. Intravenous amphotericin B is
the drug of choice [8]. Fluconazole can be used in haemo-
dynamically stable patients and who have not had recent
therapy with fluconazole, or those who have a fluconazole-
susceptible organism [8]. Although there is an effective anti-
fungal therapy, removal of implantable device is required [8].Fungal septicaemia should be considered in patients with
CF who have exacerbation not responding to the usual
treatment.
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